Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperlipidemia and renal disease]

N Yorioka1

  • 1Second Department of Internal Medicine, Hiroshima University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 16, 2001
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2010
Same author

Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2010
Same author

Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.

Clinical nephrology·2009
Same author

Oral mizoribine pulse therapy for steroid-dependent focal segmental glomerulosclerosis.

Clinical nephrology·2008
Same author

Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS).

Clinical nephrology·2007
Same author

PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation.

Clinical and experimental immunology·2006